Project Grant R21AI199162
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $221K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Scottsdale, AZ 85259, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a Project Grant of $3,075,549 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 28, 2025, with a completion date of June 30, 2029. This research initiative investigates airway innate immune responses to Coccidioides infection, a serious fungal disease commonly known as valley fever that is expanding geographically across the United States. The research focuses on...
- The National Institute of Allergy and Infectious Diseases awarded the Regents of the University of Michigan $677,822 on June 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to estimate and understand population susceptibility to coccidioidomycosis, an emerging fungal infectious disease in the U.S. Southwest. The project advances methods for estimating immunity to Coccidioides in the general population using cell-mediated immunity tests and population-level...
- The National Institute of Allergy and Infectious Diseases awarded $712,977 to Northern California Institute For Research And Education, Inc. on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of human natural killer cells in immune response to Coccidioides. The research maps coccidioides lung granulomas at single-cell resolution in patient specimens and models acute infection in human lung tissue explants to characterize early...
- The National Institute of Allergy and Infectious Diseases awarded the University of California, San Diego $420,228 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to determine the effects of ambient dust exposure and extreme dust events on coccidioidomycosis incidence in Arizona. The recipient will conduct a secondary data analysis study leveraging a spatiotemporally refined dust concentration database and over 126,000 reported coccidioidomycosis cases...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $441,100 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research targeting phosphoglucomutase in Pneumocystis pneumonia. The research addresses the glucan-rich cell wall of Pneumocystis, which synthesizes β-glucans from uridine diphosphate glucose, a pathway requiring phosphoglucomutase (PGM) to interconvert glucose-6-phosphate and glucose-1-phosphate. Prior...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $443,850 on February 4, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how intestinal exposure to Candida albicans in early life influences developing immune responses, specifically T cell responses and the differentiation of T helper 17 cells that produce the inflammatory cytokine IL-17. The research addresses the growing epidemic of immune-mediated diseases in...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $100,228 on November 23, 2026, to develop and evaluate novel biostatistical methods for human microbiome metagenomic data analysis under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds two primary research aims. In Aim 1, the recipient will systematically evaluate widely used methods for analyzing longitudinal microbiome data—specifically mixed-effects models—and develop a simpler...
- The National Institute of Allergy and Infectious Diseases awarded Triad National Security, LLC $520,223 on June 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct environmental sampling for the fungal pathogen Coccidioides spp. in New Mexico. The recipient will collect soil samples throughout New Mexico to identify ecosystems conducive to Coccidioides growth, determine the geographical distribution of each Coccidioides species, and assess whether...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic Arizona $638,403 on August 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the roles of group 2 innate lymphoid cells (ILC2s) in type 2 immunity and asthma. The project examines immunological mechanisms underlying airway inflammation in asthma patients, focusing on how ILC2s—which rapidly produce type 2 cytokines—regulate adaptive immune responses in the lungs and...
- The National Institute of Allergy and Infectious Diseases awarded Mayo Clinic $800,097 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop methods for improving antinuclear antibody (ANA) testing and understanding autoimmune disease progression in ANA-positive individuals. The project leverages epidemiological data, biobank resources, and artificial intelligence technologies to address two key knowledge gaps: the long-term risk of autoimmune...